北京康比特体育科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 □业绩说明会 □媒体采访 证券代码：833429 证券简称：康比特 公告编号：2024-068 □路演活动 √其他 （线上会议、电话会议、券商策略会） 二、 投资者关系活动情况 活动时间：2024 年 10 月 29 日至 2024 年 11 月 14 日 活动地点：进门财经 APP、公司会议室、线上交流、上海浦东香格里拉大酒 店 参会单位及人员：中信建投基金、南方基金、华安基金、汇添富基金、国寿 安保基金、北信瑞丰基金、信达澳银基金、中天汇富基金、中国人寿资产、九泰 基金、东吴基金、开源证券、华源证券、中金公司、山西证券、国投证券、第一 创业证券、浙商证券、招商基金、长江证券、中颖投资、天驷资产、九祥资产、 汇瑾资产、冰河资产、八零后资产、弘毅远方、财信证券、指南创业投资、星允 投资、南山京石投资、君创富民资产、东北证券、东吴证券、天治基金、申万宏 源、纽富斯 ...

证券代码：833429 证券简称：康比特 公告编号：2024-069 章 程 二零二四年十一月 1 北京康比特体育科技股份有限公司 | | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 股份发行 | 4 | | 第二节 股份增减和回购 | 5 | | 第三节 股份转让 | 7 | | 第四章 | 股东和股东大会 8 | | 第一节 股东 | 9 | | 第二节 | 股东大会的一般规定 12 | | 第三节 股东大会的召集 | 17 | | 第四节 股东大会的提案与通知 | 19 | | 第五节 股东大会的召开 | 20 | | 第六节 股东大会的表决和决议 | 23 | | 第五章 | 董事会 27 | | 第一节 | 董事 27 | | 第二节 | 董事会 31 | | 第三节 | 董事会秘书 36 | | 第四节 | 独立董事 38 | | 第六章 | 总经理及其他高级管理人员 42 | | 第七章 | 监事会 44 | | 第一节 | 监事 44 | | 第二节 | 监事会 45 | | 第三节 | 监事会 ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2] Core Views - The company has shown robust revenue growth, with a year-on-year increase of 20.13% in Q3 2024 and a cumulative revenue of 774 million yuan for the first three quarters of 2024, representing a 29.84% increase year-on-year [5] - The company is increasing its investment in the "Sports Nutrition Food Production Base Construction Project," raising the planned investment from 126 million yuan to 309 million yuan due to rapid market demand for solid and liquid products [6] - The company is expected to benefit from the high demand in the sports nutrition industry, with a strong competitive edge in product quality and channel distribution [7] Financial Performance - The company achieved a net profit of 66 million yuan in the first three quarters of 2024, a 2.06% increase year-on-year, while the non-recurring net profit rose by 27.25% to 65 million yuan [5] - The gross profit margin for Q3 2024 was 37.64%, down 3.18 percentage points year-on-year, primarily due to rising raw material costs [6] - The company forecasts revenues of 1,001 million yuan for 2024, with a year-on-year growth of 18.8%, and net profits of 98 million yuan, reflecting an 11% increase [10] Valuation and Earnings Forecast - The estimated earnings per share (EPS) for 2024, 2025, and 2026 are projected to be 0.79 yuan, 0.99 yuan, and 1.25 yuan respectively [10] - The company is assigned a price-to-earnings (P/E) ratio of 16-20 times for 2025, leading to a reasonable valuation range of 15.84 to 19.8 yuan per share [7]

证券代码：833429 证券简称：康比特 公告编号：2024-067 北京康比特体育科技股份有限公司 回购进展情况公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 回购方案基本情况 公司董事会审议通过回购股份方案前 30 个交易日（不含停牌日）交易均价为 10.00 元，拟回购价格上限不低于上述价格，不高于上述价格的 200%。为保护投资者利益， 结合公司目前的财务状况、经营状况及近期公司股价，确定本次回购价格不超过 13 元/ 股，具体回购价格由公司股东大会授权董事会在回购实施期间，综合公司二级市场股票 价格、公司财务状况和经营状况确定。 自董事会决议至回购完成期间，如公司存在权益分派等事项，将自权益分派实施之 日起，及时调整回购价格。 调整公式为：P＝（P0﹣V*Q/Q0）/（1+n） 其中：P0 为调整前的回购每股股份的价格上限；V 为每股的派息额；Q 为扣除已回 购股份数的公司股份总额；Q0 为回购前公司原股份总额；n 为每股公积金转增股本、派 送股票红利、股票拆细的比率（即每股股票经转 ...

回购进展情况公告 证券代码：833429 证券简称：康比特 公告编号：2024-067 北京康比特体育科技股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 回购方案基本情况 （一） 审议及表决情况 北京康比特体育科技股份有限公司（以下简称"公司"）于 2024 年 8 月 26 日召开 第六届董事会第七次会议、第六届监事会第七次会议，审议通过《关于公司回购股份方 案的议案》，根据《北京证券交易所上市公司持续监管指引第 4 号——股份回购》《公司 章程》等相关规则制度规定，本事项无需提交股东大会审议。 （二） 回购股份的目的 基于对公司未来发展的信心和对公司价值的认可，提升公司股票长期投资价值，综 合考虑公司经营情况、财务状况以及未来的盈利能力等因素，公司拟以自有资金回购公 司股份。本次回购的股份将用于实施股权激励，以此进一步完善公司治理结构，构建长 期激励与约束机制，确保公司长期经营目标的实现，提升公司整体价值。 （三） 回购股份的种类、方式、价格区间 本次回购方式为竞价方式回购，回购股 ...

Investment Rating - The report maintains a "Recommended" rating for the company 康比特 (833429.BJ) [4] Core Views - The company reported a revenue of 774 million yuan for the first three quarters of 2024, representing a year-on-year growth of 29.84%. The net profit attributable to shareholders was 65.56 million yuan, a slight increase of 2.06% year-on-year, while the non-deductible net profit grew by 27.25% to 64.91 million yuan [1] - The company is increasing its investment in production capacity due to rising demand for its products, planning to raise the total investment for its "Sports Nutrition Food Production Base" project from 126 million yuan to 309 million yuan, with an expected completion date in August 2026 [2] - Continuous product innovation is a focus, with new product launches expected to capture a larger market share in the growing sports nutrition sector, which is still in its early stages in China [2] - The domestic sports nutrition industry is projected to maintain a high level of prosperity, with the company positioned as a leader in the market, benefiting from both online and offline sales channels [2] Financial Forecasts - The company is expected to achieve revenues of 1.012 billion yuan, 1.202 billion yuan, and 1.422 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding net profits of 100 million yuan, 121 million yuan, and 135 million yuan [3] - The earnings per share (EPS) are projected to be 0.80 yuan, 0.97 yuan, and 1.08 yuan for the same years, with price-to-earnings (PE) ratios of 19.93, 16.42, and 14.78 [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [1][4]. Core Insights - The company achieved a revenue of 774 million yuan in Q1-Q3 2024, a year-on-year increase of 29.84%, and a net profit attributable to shareholders of 65.56 million yuan, up 2.06% from the previous year. The net profit excluding non-recurring items increased by 27.25% [2]. - The growth in revenue is primarily driven by the expansion of the sports nutrition and general nutrition product lines, supported by increased marketing efforts, which saw sales expenses rise by 48.84% to 128 million yuan [2]. - The sports industry is experiencing growth due to national policies promoting sports development, with the number of fitness enthusiasts in China expected to exceed 460 million by 2027, creating favorable conditions for the demand for sports health products [3]. - The company has been increasing its R&D investment, with an average R&D expenditure of 18.66 million yuan from 2018 to 2022, and a significant increase to over 30 million yuan in 2023, reflecting its strong R&D capabilities [3]. - The company is expected to achieve net profits of 104 million yuan, 123 million yuan, and 144 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.83 yuan, 0.99 yuan, and 1.16 yuan per share [4]. Financial Summary - Total revenue is projected to grow from 843.22 million yuan in 2023 to 1,404.06 million yuan in 2026, with a compound annual growth rate (CAGR) of 14.86% [1][4]. - The company's net profit is expected to increase from 88.10 million yuan in 2023 to 143.85 million yuan in 2026, with a CAGR of 17.24% [1][4]. - The current P/E ratios are projected to decrease from 22.61 in 2023 to 13.85 in 2026, indicating an attractive valuation as earnings grow [1][4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [1][4]. Core Insights - The company achieved a revenue of 774 million yuan in Q1-Q3 2024, a year-on-year increase of 29.84%, and a net profit attributable to shareholders of 65.56 million yuan, up 2.06% from the previous year. The net profit excluding non-recurring items increased by 27.25% year-on-year [2]. - The growth in revenue is primarily driven by the expansion of the sports nutrition and general nutrition product lines, supported by increased marketing efforts, which saw sales expenses rise by 48.84% to 128 million yuan [2]. - The company is well-positioned to benefit from the growing sports industry in China, with the number of fitness enthusiasts expected to exceed 460 million by 2027, creating a favorable environment for the demand for sports health products [3]. - Continuous investment in research and development has strengthened the company's competitive edge, with R&D expenses increasing to over 30 million yuan in 2023, reflecting a compound annual growth rate of 19.37% [3]. Financial Forecast and Valuation - The company is projected to achieve net profits of 104 million yuan, 123 million yuan, and 144 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.83 yuan, 0.99 yuan, and 1.16 yuan per share [4]. - The current price-to-earnings (P/E) ratios are estimated at 19, 16, and 14 times for the years 2024, 2025, and 2026, respectively, indicating a favorable valuation relative to expected earnings growth [4].

证券代码：833429 证券简称：康比特 公告编号：2024-061 已经就本次募集资金的存放签订了《募集资金三方监管协议》，募集资金已存储 于募集资金专户。 二、募集资金投资项目的具体情况 根据公司《招股说明书》，公司本次公开发行股票的募集资金将用于投资以 下项目： 其中，"品牌建设与推广项目"已结项，详见《关于注销部分募集资金专项账户的公告》 （公告编号：2024-041）、《2024 年半年度募集资金存放与实际使用情况的专项报告》（2024- 046）。 北京康比特体育科技股份有限公司 关于增加部分募投项目投资规模的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 北京康比特体育科技股份有限公司（以下简称"公司"）于2024年10月25日 召开第六届董事会第八次会议、第六届监事会第八次会议，审议通过了《关于增 加部分募投项目投资规模的议案》，同意"运动营养食品生产基地建设项目"增 加投资规模。保荐机构出具了无异议的核查意见，本事项尚需提交公司股东大会 审议批准。现将具体事项公告如下： 一、募集 ...

证券代码：833429 证券简称：康比特 公告编号：2024-060 北京康比特体育科技股份有限公司 第六届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 公司 2024 年第三季度报告的编制和保密程序符合法律、法规、《公司章程》 和公司管理制度的各项规定；本次第三季度报告的内容和格式符合中国证监会和 北京证券交易所的各项规定，其内容真实、准确、完整，不存在任何虚假记载、 误导性陈述或者重大遗漏，报告客观地反映了公司 2024 年第三季度的财务及经 营状况。 1.会议召开时间：2024 年 10 月 25 日 2.会议召开地点：公司会议室 3.会议召开方式：现场和通讯 4.发出监事会会议通知的时间和方式：2024 年 10 月 22 日以书面方式发出 5.会议主持人：许来宾 6.召开情况合法、合规、合章程性说明： （一）审议通过《2024 年第三季度报告》 1.议案内容： 具体内容详 ...